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Abstract
Introduction: Understanding relationships among blood pressure (BP), cognition, and
brain volume could informAlzheimer’s disease (AD)management.
Methods: We investigated Alzheimer’s Disease Neuroimaging Initiative (ADNI) par-
ticipants: 200 controls, 346 mild cognitive impairment (MCI), and 154 AD. National
Alzheimer’s Co-ordinatingCenter (NACC) participantswere separately analyzed: 1098
controls, 2297 MCI, and 4845 AD. Relationships between cognition and BP were
assessed in both cohorts and BP and atrophy rates in ADNI. Multivariate mixed linear-
regression models were fitted with joint outcomes of BP (systolic, diastolic, and pulse
pressure), cognition (Mini-Mental State Examination, Logical Memory, and Digit Sym-
bol) and atrophy rate (whole-brain, hippocampus).
Results: ADNI MCI and AD patients with greater baseline systolic BP had higher hip-
pocampal atrophy rates ([r, P value]; 0.2, 0.005 and 0.2, 0.04, respectively). NACC AD
patients with lower systolic BP had lower cognitive scores (0.1, 0.0003).
Discussion: Higher late-life BP may be associated with faster decline in cognitively
impaired elders.
K EYWORD S
Alzheimer’s disease, blood pressure, cognitive decline, hypertension, hypotension, longitudinal,
mild cognitive impairment
1 BACKGROUND
Hypertension is related to cognitive decline and dementia,1 includ-
ing Alzheimer’s disease (AD).2,3 The link between hypertension and
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided
the original work is properly cited.
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brain tissue loss (atrophy rate), is poorly understood, with conflicting
results.4–7
Hypertension may be a modifiable risk factor not just for preven-
tion, but also progression of AD.8 The rate of progression in AD is
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heterogeneous and blood pressure (BP) may partially account for this
variability.
Atrophy rate is a biomarker of AD progression, and an important
outcome measure in clinical trials.9 It is necessary to understand how
BP associateswith atrophy rates to enable effective planning of clinical
trials in which they are used as outcomemeasures.
Targeting BP in the same way across the cognitive spectrum may
not be appropriate.10 LowBP is associatedwith poorer cognition in the
elderly11 and is common in AD patients.11,12 Falling BP is also associ-
ated with worsening cognition in the hypertensive elderly.13
Here, we aimed to understand relationships among late-life BP, cog-
nition, and brain volume in 700 participants from the Alzheimer’s Dis-
easeNeuroimaging Initiative (ADNI).We also investigated BP and cog-
nition in a group of 8240 participants from a complementary dataset:
National Alzheimer’s Coordinating Center (NACC). We hypothesized
that BP would be associated with brain volume change; changes in
BP would be associated with changes in brain volume. Similarly, we
hypothesized that baseline BP would be associated with baseline neu-
ropsychology and change in neuropsychology.We also considered that
BP changes would be associated with changes in neuropsychology.
2 METHODS
2.1 Participants
2.1.1 ADNI
We obtained data from the ADNI database (adni.loni.usc.edu).
Data are freely available for qualified researchers. Participants
engaged in baseline clinical, neuropsychometric, and magnetic res-
onance imaging (MRI) assessments and periodical assessments
thereafter. Written informed consent was obtained from each par-
ticipant and approved by the Institutional Review Board at each
of the >50 participating centers. ADNI is a multicenter longitudi-
nal private-publicly funded study launched in 2003 investigating
healthy controls, mild cognitive impairment (MCI), and AD partic-
ipants. Based in America, ADNI is headed by Michael W. Weiner.
The principle goal of ADNI has been to test whether use of serial
MRI, positron emission tomography (PET), biomarkers, and clinical
and neuropsychological data could measure the progression of MCI
and early AD. For up-to-date information see www.adni-info.org.
All participants were from the first phase of the study (ADNI1).
All MCI and AD patients had an amnestic impairment. AD patients
met criteria for probable AD according to the NINCDS-ADRDA
criteria.14 For in-depth eligibility criteria, please see http://adni.
loni.usc.edu/wp-content/uploads/2010/09/ADNI_GeneralProcedures
Manual.pdf and section 1.1 in the supporting information. In brief, all
ADNI subjects had to be between 55 and 90 years at enrolment, be
English or Spanish speaking, and have a partner able to provide an
independent evaluation of functioning. Individuals taking specific psy-
choactive medications were excluded. We included patients enrolled
in ADNI1 fromSeptember 2005 to 2010. The study schedule consisted
RESEARCH INCONTEXT
1. Systematic review: We reviewed the literature using
PubMed. There has been substantial recent interest in
the relationships of blood pressure, cognition, and atro-
phy. The relevant publications have been cited in the
manuscript.
2. Interpretation:Our findings demonstrate that potentially
modifiable variables are associated with volume change
in the brain in clinical Alzheimer’s disease (AD). Our
results also show there is a need to monitor blood pres-
sure in late life including in individuals with cognitive
impairment.
3. Future directions: Further research is required to (a)
understand the mechanisms of late-life hypertension and
hypotension in neurodegeneration and cognitive impair-
ment; (b) develop appropriate blood pressure levels for
those in old age, and for those elderly with cognitive
impairment; and (c) investigate whether stratification of
clinical trials for putative AD treatments by blood pres-
suremeasurements is useful.
of visits at baseline, 6 months, 12 months, 24 months, and 36 months.
There were alterations to this schedule for disease groups; MCIs had
an additional 18-month visit and AD participants had their final visit at
24months.
2.1.2 NACC
We included participants from the NACC data set (http://www.
alz.washington.edu/), from theMarch2014data freeze.Data are freely
available for the research community. NACC has developed and main-
tains a database of standardized clinical research visits, collected from
39 past and present NIA-funded Alzheimer’s Disease Centers (ADCs)
in the United States. The recruitment of participants and data collec-
tion in NACC has been described previously.15,16 Institutional review
boards at eachADCapproved the study.Written and informed consent
was given by all NACC participants.
We included patients seen at 34 ADCs from its inception in 2005
to February 2014. All participants visited for research purposes and
were not enrolled in ADNI1 (Figure S1 in supporting information).
Imaging data were unavailable for the majority of subjects; therefore,
for NACCwe investigated BP and cognition relationships only. Criteria
on MCI diagnosis for ADCs was developed using consensus guidelines
set by an expert panel.17 MCI patients were included if they had
memory problems. AD patients were demented with a diagnosis
of probable or possible AD at first visit.14 We excluded individuals
with secondary causes of dementia (see section 1.1 in supporting
information).
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2.2 BP readings
Seated systolic blood pressure (SBP) and diastolic blood pressure
(DBP) readings were measured at all visits for ADNI and at approxi-
mately annual visits for NACC (see section 1.2 in supporting informa-
tion). Pulse pressure (PP) was calculated as SBPminus DBP.
2.3 Image analysis
The ADNI MRI protocol is detailed elsewhere.18 After the acquisition,
quality control was completed and ADNI image pre-processing was
then applied, including gradient warping,19 B1 non-uniformity,20 and
intensity non-uniformity correction.21 Imaging data consisted of all
availableADNI1 timepoints frombaseline to 36months (0-, 6-, 12-, 18-,
24-, and36-month scans),with aT1-weightedvolumetric scanacquired
on a 1.5T scanner of sufficient quality. Internal visual quality control
was performed, excluding images with severe blurring of tissue bound-
aries due to motion artefacts. Whole-brain and hippocampal volumes
were estimated automatically from the 1.5T volumetric T1-weighted
imagesusingBMAPS22 andHMAPS, respectively.23 Theboundary shift
integral (BSI)wasused toestimate changedirectly fromscanpairs after
segmentation,24 the outcome representing change in volume ofwhole-
brain or hippocampus (mL) during the scan interval. Total intracranial
volume (TIV), a proxy for head size, was also calculated.25
2.4 Cognition
We investigated three longitudinal cognition outcomes: Mini-Mental
State Examination (MMSE) for global impairment, Logical Memory
Immediate Story Recall (LM) for memory,WAIS-R Digit Symbol (DSST)
for processing speed. Examinations were administered at each visit,
apart from LM in ADNI, which was administered annually.
2.5 Statistical models
2.5.1 Demographic information
Demographic differences between groups for continuous outcomes
were tested using analysis of variance; Fisher’s exact test was used for
categorical outcomes. TIV was used as a covariate for brain and hip-
pocampal outcomes.
2.5.2 Joint modeling of outcomes
We jointly modeled change in BP (using SBP, DBP, and PP in sepa-
ratemodels), change in cognition, and change inbrain/hippocampal vol-
ume. Therewas no “predictor” aswith traditional regressionmodels; to
observe concurrent changes in BP, cognition, and atrophy, each of the
three variables were jointly modeled as outcomes. Multivariate mixed
linear-regression models were fitted with outcomes of BP (SBP, DBP,
PP), atrophy (whole-brain, hippocampal change), and cognition (MMSE,
LM, DSST). A random intercept (BP, atrophy rate, and cognition) and
randomslopewere included for the participant levelwith unstructured
covariance to allow for correlations among all random effects, apart
from the random intercept for atrophy rate. The atrophy rate random
intercept was included to account for the random measurement error
at the first scan, which would be shared between all atrophy mea-
sures. Likelihood ratio tests were used to test random effects corre-
lations between outcomes. The following correlations were examined:
(1) baseline BP, change in brain volume; (2) change in BP, change in
brain volume; (3) baseline BP, baseline neuropsychology; (4) baseline
BP, change in neuropsychology; (5) change in BP, change in neuropsy-
chology. Models were run separately in each diagnostic group.
No fixed effects intercept was included in the model for change in
brain volume due to the assumption that the estimated atrophy rate
over a scan interval of zero is zero. As no intercept, or measure of
baseline volume change, is estimated using BSI (volume change) data,
we separately modeled baseline brain and hippocampal volume in a
regression model (see below). We used the multilevel modeling soft-
ware MLWin version 2.36, February 2016 release.26 For BP and cog-
nitive models, age and sex were added as covariates to adjust for their
associations with the baseline value of these outcomes, and for all out-
comes these covariates were interacted with time, to adjust for their
associations with changes in outcome. Apolipoprotein E (APOE) 𝜀4 sta-
tus (binary covariate indicating presence or absence of an 𝜀4allele)was
included in the relevant ADNI models to adjust for associations with
baseline BP, baselineMMSE,MMSE change, and brain volume change.
Fixed effects data are tabulated in supporting information. Due to
lack of any detectable change over time in SBP and DBP for ADNI
AD patients the random effect slope for change in blood pressure was
removed to allow themodel to converge. For PP in the ADNI AD group
the random effect slope was permitted, but the random effect correla-
tion between baseline PP and change in PPwas omitted.
For NACC, models were also fitted with adjustment for antihyper-
tensive medication use and also for APOE𝜀4 (binary covariate indicat-
ing presence or absence of an 𝜀4 allele), see section 1.3 in supporting
information.
In ADNI, to investigate correlations between baseline BP and base-
line whole-brain/hippocampal volumes, regressionmodels were fitted,
with separate outcomesofwhole-brain/hippocampal volumeandbase-
line BP (either SBP, DBP, or PP) as the predictor. Age, APOE 𝜀4 status,
TIV, and sex were included as covariates.
2.5.3 Analysis by hypertensive status in AD
AD patients were categorized by hypertensive status based upon
initial BP and antihypertensive usage. BP cut-offs for hypertension
were defined as = >140 mmHg for SBP and/or = >90 mmHg for
DBP.27 Hypotension was defined as SBP = < 90 mmHg and/or = <60
mmHg for DBP, as defined by the United States Institutes of Health
(https://www.nhlbi.nih.gov/health-topics/hypotension). Demographics
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TABLE 1 Subject demographics and basic imaging information for the Alzheimer’s disease Neuroimaging Initiative (ADNI) and National
Alzheimer’s Co-ordinating Center (NACC) cohorts
ADNI NACC
Controls
Mild cognitive
impairment
Alzheimer’s
disease
Group
differ-
ence
(P value) Controls
Mild cognitive
impairment
Alzheimer’s
disease
Group
differ-
ence
(P value)
N 200 346 154 1098 2297 4845
Follow-up length (years) 2.6 (0.8) 2.3 (0.8) 1.7 (0.6) <0.01 4.5 (1.8) 2.4 (2.0) 1.4 (1.7) <0.01
Number of time points
(min., max.)
3.2 (1, 4) 3.6 (1, 5) 2.3 (1, 3) <0.01 4.9 (1, 7) 3.0 (1, 7) 2.3 (1, 7) <0.01
Age at baseline (years) 76.0 (5.2) 75.0 (7.2) 75.0 (7.7) 0.22 78.1 (8.7) 75.3 (9.1) 75.5 (10.0) <0.01
Percentagemale 53 63 54 0.02 38 50 47 <0.01
Percentage APOE𝜀4^ 26 55 69 <0.01 36 45 59 <0.01
Years of education 16.1 (2.8) 15.7 (3.0) 14.8 (3.0) <0.01 15.8 (7.4) 15.4 (5.4) 14.9 (8.7) <0.01
Total brain vol. (mL) 1068.0 (103.1) 1061.9 (114.6) 1022 .0 (115.1) <0.01# n/a
Total hippocampal vol. (mL) 5.2 (0.7) 4.5 (0.8) 3.9 (0.9) <0.01# n/a
Baseline SBP* (mmHg) 133.9 (16.3) 134.4 (17.9) 137.5 (17.2) 0.1 135.2 (18.2) 136.0 (18.9) 134.9 (19.2) 0.09
Baseline DBP* (mmHg) 74.4 (10.3) 74.5 (9.5) 74.4 (9.5) 0.9 73.5 (10.2) 74.8 (10.4) 74.5 (10.9) <0.01
Baseline pulse pressure*
(mmHg)
59.4 (15.2) 59.9 (15.8) 63.1 (16.5) 0.07 61.7 (16.5) 61.2 (16.6) 60.4 (17.0) 0.03
BaselineMMSE, /30 29.1 (1.0) 27.0 (1.8) 23.4 (1.9) <0.01 28.5 (1.6) 26.9 (2.5) 19.7 (6.8) <0.01
Baseline LM, /25 13.9 (3.4) 7.1 (3.1) 3.9 (2.8) <0.01 12.1 (3.9) 8.4 (4.0) 4.0 (3.6) <0.01
Baseline DSST**, /93 46.0 (10.2) 37.0 (11.2) 27.5 (12.4) <0.01 41.0 (11.8) 37.1 (12.0) 24.8 (14.1) <0.01
Percentage hyper-
cholesteremic***
25 30 36 0.09 45 52 47 0.04^
Percentage diabetic▲ 6 7 6 0.9 10 13 12 <0.001^
Percentage smoker (past or
current)▲▲
40 42 40 0.9 42 46 43 0.03
Percentage on
antihypertensive
medication at baseline
▲▲▲
n/a 62% 60% 54% <0.01
Values aremean (standard deviation) unless reported. Systolic blood pressure (SBP) and diastolic blood pressure (DBP), MMSE (Mini-Mental State Examina-
tion), LM (logical immediate story recall) and DSST (WAIS-R Digit Symbol) are investigated. # Adjusted for TIV. ^Data missing in 199 NACC control subjects,
873 NACC mild cognitive impairment patients and 1861 NACC Alzheimer’s disease patients. *data missing in 91 NACC subjects. **data missing in 63 ADNI
subjects, ***data missing in 90 NACC subjects,▲ data missing in 35 NACC subjects,▲▲ data missing in 120 NACC subjects,▲▲▲ data missing in 97
NACC subjects. The proportion of NACC individuals with hypertensive baseline BP readings, who were not on antihypertensive medication was calculated
as a percentage. ^ figures and p value exclude subjects with remote or inactive hypercholesterolemia (remote/inactive hypercholesterolemia 3% for controls;
3%MCI; 4%AD) or remote/inactive diabetes (0.4% control, 1%MCI, 1%AD) for NACC participants.
for groups and fixed effects resulting from the models are tabulated in
Table S7 in supporting information.
For information on figures and tabulation see section1.4 in support-
ing information. For reference we ran all graphically presented effects
without adjustment for covariates.
3 RESULTS
3.1 Demographic information
After quality control, 700 ADNI participants were included in this
study (see Figure S1). MCI and AD patients had lower brain and hip-
pocampal volumes, greater cognitive impairment, andweremore likely
to be an APOE 𝜀4 carrier than controls (Table 1).
A total of 8240 NACC participants were suitable for the present
study. Controls were older and were more likely to be female, com-
paredwithMCI and AD groups.
3.2 Control results
From both ADNI and NACC, controls on average had no signifi-
cant change in BP over time (see Table S1 in supporting informa-
tion). ADNI controls had significant rates of brain and hippocam-
pal volume loss, but did not decline in cognition over time. The
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F IGURE 1 Relationships between baseline blood pressure (BP) and baseline psychology or hippocampal volume. Graphs to demonstrate
relationships between baseline blood pressure and baseline psychology or hippocampal volume (Alzheimer’s Disease Neuroimaging Initiative
[ADNI] denoted by blue crosses andNACC [National Alzheimer’s Co-ordinating Center] by red). Predicted values from linear regression of
baseline diastolic BP (DBP) and baseline whole-brain volume in ADNI control participants (a); All others, graphs of participant level residuals,
demonstrating random effect correlations between: (B) baseline DBP and baselineMini-Mental State Examination (MMSE) in ADNI controls; (C)
baseline systolic BP (SBP) and baseline Logical Memory Immediate Story recall (LM) in NACC controls; (D) baseline SBP and baselineMMSE in
NACCAlzheimer’s disease patients. All ADNI relationships are corrected for APOE genotype, age, sex, and total intracranial volume. All NACC
relationships adjusted for age and sex. Results for models without covariate adjustment are also shown. ^ Similar relationship exists for pulse
pressure.
larger group of NACC controls had, on average, a decline in MMSE
and LM.
3.2.1 BP and atrophy
ADNI control participants with higher baseline DBP had lower base-
line brain volumes, see Figure 1a, Table S2 in supporting information,
corresponding to a -0.88 mL decrease for a 1 mmHg increase in dias-
tolic BP, from the average brain volume of 1132 mL (estimate, [95%CI]
(P value); (–0.88 [–1.59, –0.17] (0.01)). However, there were no signif-
icant correlations between baseline, or change in, blood pressure and
brain/hippocampal volume change over time (Table S3 in supporting
information).
3.2.2 BP and neuropsychology
In both cohorts, higher BP tended to be associated with worse base-
line neuropsychology scores in controls, although this was not found
across all measures. In ADNI, controls with higher baseline DBP had
a worse baseline MMSE score (correlation coefficient, P value) (–0.24,
0.05) (seeFigure1B, Table S4 in supporting information). InNACC, con-
trols with higher SBP had lower baseline LM (–0.13, 0.01) (see Table 2,
Figure 1C). NACC controls with higher PP also had lower DSST scores
(–0.12, 0.01). No correlations were found between changes in BP and
changes in neuropsychology.
3.3 MCI results
In both ADNI and NACC, MCI participants had falling DBP over time
(Table S1). ADNI MCI participants declined in MMSE and DSST over
time, but not LM. NACC MCI participants showed significant rates of
decline in all neuropsychologymeasures.
3.3.1 BP and atrophy
For ADNI MCI patients, higher baseline SBP was associated with
higher hippocampal atrophy rates (correlation coefficient, P value)
(0.20, 0.005) (see Table 3, Figure 2A) and those with higher PP also had
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TABLE 3 Systolic blood pressure (SBP), diastolic blood pressure
(DBP), and pulse pressure (PP) and hippocampal volume change are
correlated in Alzheimer’s Disease Neuroimaging Initiative (ADNI1)
ADNI BP and
hippocampal atrophy
rate correlation Controls
Mild
cognitive
impairment
Alzheimer’s
disease
Baseline SBP 0.01 (0.96) 0.20 (0.005) 0.23 (0.04)
Baseline DBP −0.12 (0.24) 0.04 (0.57) 0.22 (0.05)
Baseline PP 0.08 (0.41) 0.21 (0.004) 0.19 (0.14)
Change in SBP −0.10 (0.48) −0.02 (0.83) Inestimable
Change in DBP 0.32 (0.17) −0.06 (0.67) Inestimable
Change in PP −0.25 (0.10) 0.00 (0.96) −0.46 (0.19)
Random effects correlations (r and [P values]) are shown. Analyses are
adjusted for sex, age, APOE 𝜀4 genotype, and total intracranial volume.
greaterhippocampal atrophy rates (0.21, 0.004).Nosignificant correla-
tionswere seen between baseline BP, or changes in BP, andwhole brain
atrophy rates.
3.3.2 BP and neuropsychology
In NACC, higher baseline SBP showed significant correlations with
lower baseline MMSE (−0.11, 0.01) (see Table 2, Figure S2a in sup-
porting information), and LM (−0.09, 0.01), and faster decline in DSST
(−0.12, 0.02) (Figure 2C). LowDBPwas related to a decline in LM (0.14,
0.02) (Figure S2b in supporting information). Higher baseline PP had
significant associations with lower baseline MMSE (−0.10, 0.02) and
LM (−0.08, 0.03), and decline in MMSE (−0.14, 0.003), DSST (−0.16,
0.003), and LM (−0.14, 0.02) (Figure S2c).
Falling SBP was associated with declining DSST (0.43, 0.0001) (Fig-
ure2D), anda similar effectwas seenwith fallingPPanddecliningDSST
(0.40, 0.00003), MMSE (0.32, 0.01), and LM (0.28, 0.01).
No correlations were found between BP and neuropsychology in
ADNI (see Table S4).
3.4 AD results
The ADNI AD group did not show any significant change over time in
BP, but falling SBP, DBP, and PP were all detected in the NACC AD
group, see Table 1.
3.4.1 BP and atrophy
Higher baseline SBP was associated with greater subsequent hip-
pocampal atrophy (0.23, 0.04) (see Table 3, Figure 2B); this relation-
ship was mirrored by DBP (0.22, 0.05) (see Table 3, Figure S2d). It
was not possible to examine associations between atrophy rates and
changes for SBP or DBP due to minimal between-participant variabil-
ity in change over time in these measures. No association was found
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F IGURE 2 Relationships between blood pressure (BP) and cognitive or hippocampal change. Graphs of participant level residuals,
demonstrating random effect correlations between baseline or change in BP and cognitive or hippocampal change (Alzheimer’s Disease
Neuroimaging Initiative [ADNI] denoted by blue crosses andNACC [National Alzheimer’s Co-ordinating Center] by red). Baseline systolic BP (SBP)
and hippocampal volume loss in ADNImild cognitive impairment (mild cognitive impairment) patients (A), and Alzheimer’s disease patients (B);
(C–D) NACCmild cognitive impairment patients; (C) baseline SBP and change in Digit Symbol (DSST); (D) SBP change andDSST change. All ADNI
relationships are corrected for APOE genotype, age, sex, and total intracranial volume. All NACC relationships adjusted for age and sex. Results for
models without covariate adjustment are also shown. ^Similar relationship exists for pulse pressure;+ similar relationship exists for diastolic blood
pressure
between change in PP and either hippocampal or whole brain atrophy
rate.
3.4.2 BP and neuropsychology
In ADNI, no significant correlations with neuropsychology were
observed. However, in NACC, higher SBP pressure and higher PPwere
associated with higher baseline MMSE (0.09, 0.0003 [Figure 1D) and
0.09, 0.0005 respectively). Falling SBP and declining PP were associ-
ated with faster declines in MMSE (0.19, 0.003 [Figure S2e] and 0.14,
0.001, respectively).
3.4.3 Analysis of AD patients by hypertensive group
andmedication
We found low baseline BP predicted low baseline MMSE in the medi-
cated hypotensives (see Table 4) ([correlation coefficient, P value] 0.37,
0.01), and the non-medicated, normotensives (0.21, 0.006). A rela-
tionship between low baseline BP and subsequent MMSE decline was
found in hypotensive groups (non-medicated [0.59, 0.04] and medi-
cated [0.43, 0.03]). An opposing relationship was found in the hyper-
tensive groups, in which high baseline BP predicted MMSE decline,
although only significantly in the non-medicated group despite equal
effect sizes (non-medicated [–0.26, 0.02], medicated [–0.26, 0.13]).
Last, both hypertensive groups showed simultaneously falling BP and
falling MMSE (non-medicated [0.58, 0.001], medicated [0.82, 0.03]).
There were no relationships between BP and cognition in the medi-
cated normotensives, despite being the largest group.
3.5 Adjustment forAPOE genotype and
antihypertensive use
With adjustment for APOE 𝜀4 genotype in NACC the overall rela-
tionships between BP and cognition were not materially changed
(Table S5 in supporting information). With adjustment for antihyper-
tensive usage in NACC (Table S6 in supporting information) all rela-
tionships remained unchanged, apart from the correlation between
declining SBP and PP and falling MMSE in AD, which was no longer
significant.
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TABLE 4 Results for Alzheimer’s disease patients split by baseline hypertensive status, random effects correlations resulting from joint models
of systolic blood pressure (SBP) andMini-Mental State Examination (MMSE) change in AD patients by hypertensive status
Hypotensive Normotensive Hypertensive
NACC Non-medicated Medicated Non-medicated Medicated Non-medicated Medicated
1. Non-medicated hypotensive 2.Medicated
hypotensive
3. Non-medicated
normotensive
4.Medicated
normotensive
5. Non-medicated
hypertensive
6.Medicated
hypertensive
N 103 156 1168 2084 928 374
Baseline BP, BaselineMMSE
correlation
0.10 (0.56) 0.37 (0.01) 0.21 (0.006) 0.02 (0.56) 0.09 (0.29) 0.02 (0.88)
Baseline BP, Change inMMSE
correlation
0.59 (0.04) 0.43 (0.03) 0.11 (0.33) −0.01 (0.83) −0.26 (0.02) −0.26 (0.13)
Change in BP, Change inMMSE
correlation
−0.55 (0.11) Inestimable −0.02 (0.92) 0.17 (0.33) 0.58 (0.001) 0.82 (0.03)
Correlation (r and [P values]) are shown for correlations between SBP andMMSE. Analyses are adjusted for sex and age.
Graphically represented results were also tested without adjust-
ment for covariates and the majority of findings were materially
unchanged (see Figures 1 and 2 and Figure S2). The relationship
between DBP and atrophy rate in AD participants changed to trend
level without covariate adjustment (Figure S2). Without covariate
adjustment the relationship between DBP and brain volume in con-
trols was no longer significant (Figure 1), and the relationship between
change in MMSE and SBP in AD was no longer significant (Figure S2);
however, for both results the effect size and direction remained similar.
4 DISCUSSION
The central finding of this study is that higher baseline BP is associated
with greater hippocampal atrophy rates inMCI and AD. This is the first
demonstration, toour knowledge, of apotentiallymodifiable risk factor
which is associatedwith hippocampal atrophy rate in clinical AD. InAD,
higher baseline BP appeared detrimental to future cognition in hyper-
tensive patients, whereas low BP was predictive of cognitive decline
in hypotensives. In hypertensive ADs, falling BP and MMSE occurred
simultaneously.
The novel observation that higher baseline BP predicts greater hip-
pocampal atrophy rate in MCI and AD has potential clinical implica-
tions. Few factors have been found which determine atrophy rate in
AD, and those that have are not currently amenable to intervention:
APOE 𝜀4 genotype, sex, baseline atrophy level, and AD pathological
load.28–32 Clinical trials targeting amyloid pathology have, to date, not
shownabeneficial impact on atrophy rates or cognition in symptomatic
individuals.33 Licensed antihypertensives are available, meaning BP
control may be a route to attenuating decline. However, because falls
of BP in hypertensive AD groups were associated with worsening cog-
nitive scores,more research is required toexaminewhether active low-
ering of BP is appropriate.
BP in late-life has been inconsistently related to cognition and cog-
nitive decline.10 High BP has been identified as a risk factor for lower
MMSE score10 and smaller whole brain volume.34 Conversely, low BP
has been found to predict greater longitudinal atrophy in cognitively
normal individualswithmanifest arterial disease.5 Wedid not find high
BP predicted atrophy rate in controls, similarly to others35–37 although
somehavedetected relationships.6,7 Thedurationof hypertensionmay
explain why dementia is most consistently associated with mid-, rather
than late-life BP.
SBP appeared to have the strongest influence on brain volumes
and cognition across the cohorts.Many relationships between SBP and
cognition inNACCweremirrored by similarly strong effects in PP. PP is
considered an indirect measure of arterial stiffness, and has also been
shown to negatively influence brain volumes and cognition.38
We found the impact of BP on cognition was dependent on disease
stage; low BP correlated with poor cognition in AD, whereas in con-
trols and MCI high BP predicted lower cognition. Falling BP tracked
with decliningMMSE in bothMCI and AD. Low BP has previously been
found to relate to poorer cognition12 and is frequently observed in old
AD patients.11,12 At the prodromal AD stage, high BP may be harmful,
potentially lowering the threshold atwhich symptoms appear (perhaps
through cerebrovascular disease); falling and subsequently low BP in
symptomatic AD may then reflect disease stage. Studies investigat-
ing long-term BP trajectories have found that hypertension, followed
by declining BP, and subsequent hypotension is associated with lower
cross-sectional brain volumes39,40 and is common in thosewhodevelop
dementia.41 One study showed that increases in BP from ages 36 to 43
years were associated with lower brain volumes at 70 years indicating
that monitoring of BP needs to happen from early adulthood.42 Low
BP is likely to impair cerebral perfusion, which may be worse in those
with histories of hypertension, due to arterial stiffening and impaired
cerebro-autoregulation.43 Elderly individualsmay also require a higher
BP to maintain adequate perfusion.12 Conversely, low BP could also
be a product of AD-related neurodegeneration in BP-regulating brain
areas.44
When the NACC AD group was categorized dependent on base-
line hypertensive status, a pattern emerged which supports careful
BP monitoring. In non-medicated hypertensives, high baseline SBP
was detrimental for future cognition, whereas in hypotensives and
non-medicated normotensives, low SBP was predictive of cognitive
decline. Interestingly, thosewith successfully loweredBPwere theonly
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group without relationships between BP and cognition, despite being
the largest group. Notably in this group, baseline SBP was more than
10mmHg higher than the non-medicated normotensives; a higher BP
may be necessary tomaintain adequate brain perfusion in old age.12
Using data from two cohorts, our study was large, with a combined
total of 8940 participants. Our models investigated longitudinal data
from three outcomes, which enabled detection of joint patterns at an
individual level.We also investigated relationships across the cognitive
spectrum. While we ran a relatively large number of models, we opted
not to correct for multiple comparisons, as our tests were hypothe-
sis driven. Follow-up was relatively short in both cohorts. It may be
that decades of follow-up are needed to fully understand the relation-
ships among BP, brain volumes, and cognition. Both cohorts have limi-
tations in generalizability because subjects enrolled in studies tend to
be younger and fitter than those in the community.45–47 Specifically to
ADNI, subjects must score ≤4 on the Hachinski scale,48 meaning their
vascular health may be better than the general population. Different
inclusion criteria were used in each cohort and thesemay influence the
results seen; for example, it may be that the likely differing amounts
of cerebrovascular disease between cohorts influenced findings. Pos-
sible differences in BP measurement protocols between the cohorts
may have further influenced results. We chose three neuropsychology
tests relevant for AD; however, further tests are available and could be
investigated. Further, we chose to investigate SBP, DBP, and PP as they
are more immediately applicable for health-care professionals; other
BPmeasures would be interesting to investigate.
Late-life high BP is the only known modifiable predictor of atrophy
rate (change in volume) in clinically defined AD. More work is required
to understand whether lowering of BP can attenuate progression in
hypertensive cognitively impaired individuals. For clinical trials target-
ing ADpathology, increased power to detect a treatment effectmay be
achieved by stratifying or adjusting for BP. Last, in AD, both hyperten-
sion and hypotension may accelerate disease course, and therefore BP
should be carefully monitored.
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